{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:14:29Z","timestamp":1789492469068,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:23:38Z","timestamp":1789489418000},"page":"753-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of locoregional therapies in cholangiocarcinoma"],"prefix":"10.1016","volume":"85","author":[{"given":"Alejandra","family":"M\u00e9ndez Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-5333","authenticated-orcid":false,"given":"Thomas C.","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4197-4951","authenticated-orcid":false,"given":"Suus Y.","family":"van Loosbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jhep.2026.07.012_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4240\/wjgs.v14.i5.442","article-title":"Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: a case series of 68 patients","volume":"14","author":"Feng","year":"2022","journal-title":"World J Gastrointest Surg"},{"issue":"9","key":"10.1016\/j.jhep.2026.07.012_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.012_bib6","unstructured":"Kidanemariam S., Gu J., Yoon J.H., et al. Cholangiocarcinoma: epidemiology and imaging-based review. R Med J (2013) 2024;107(5):43\u201348."},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2026.07.012_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/liv.14089","article-title":"Surgery for cholangiocarcinoma","volume":"39","author":"Cillo","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"issue":"10391","key":"10.1016\/j.jhep.2026.07.012_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blnd, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jhep.2026.07.012_bib11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.30488","article-title":"Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients","volume":"123","author":"Yamashita","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1245\/s10434-023-14419-x","article-title":"The influence of hepatic steatosis and fibrosis on postoperative outcomes after major liver resection of perihilar cholangiocarcinoma","volume":"31","author":"van Keulen","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.jhep.2026.07.012_bib13","article-title":"Primary percutaneous stenting for palliative biliary drainage of patients with malignant hilar biliary obstruction: TESLA trial","volume":"7","author":"Franssen","year":"2025","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jhep.2026.07.012_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163991","article-title":"Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: the STRONG trial, a phase I safety and feasibility study","volume":"13","author":"Baak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.07.012_bib17","first-page":"JCO2500923","article-title":"Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial","author":"Franssen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.07.012_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2026.07.012_bib20","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","article-title":"Radiofrequency ablation and microwave ablation in liver tumors: an update","volume":"24","author":"Izzo","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5152\/dir.2019.18552","article-title":"Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival","volume":"26","author":"Lee","year":"2020","journal-title":"Diagn Interv Radiol"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/02656736.2017.1327678","article-title":"Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma","volume":"34","author":"Zhang","year":"2018","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.jhep.2026.07.012_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8732521","article-title":"Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma","volume":"2016","author":"Seidensticker","year":"2016","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib25","first-page":"589","article-title":"The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth","volume":"75","author":"Ackerman","year":"1974","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib26","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.jhep.2026.07.012_bib27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"10.1016\/j.jhep.2026.07.012_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000324704","article-title":"Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?","volume":"80","author":"Kemeny","year":"2011","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.07.012_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2407-7-69","article-title":"Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach","volume":"7","author":"Hildebrandt","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2026.07.012_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1234342","article-title":"Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266707","article-title":"Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma","volume":"17","author":"Ishii","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jhep.2026.07.012_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00330-021-08216-x","article-title":"Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"32","author":"Kim","year":"2022","journal-title":"Eur Radiol"},{"issue":"12","key":"10.1016\/j.jhep.2026.07.012_bib34","first-page":"4575","article-title":"Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience","volume":"31","author":"Giorgio","year":"2011","journal-title":"Anticancer Res"},{"issue":"44","key":"10.1016\/j.jhep.2026.07.012_bib35","article-title":"Treatment of intrahepatic cholangiocarcinoma: evidence for the role of percutaneous ablation","volume":"9","author":"Bale","year":"2023","journal-title":"Hepatoma Res"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0039-1696649","article-title":"Ablation of intrahepatic cholangiocarcinoma","volume":"36","author":"Sweeney","year":"2019","journal-title":"Semin Intervent Radiol"},{"issue":"2","key":"10.1016\/j.jhep.2026.07.012_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","article-title":"Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial","volume":"26","author":"van der Lei","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s43018-025-01058-2","article-title":"Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial","volume":"7","author":"Gu","year":"2026","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2026.07.012_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092655","article-title":"Interventional treatment strategies in intrahepatic cholangiocarcinoma and perspectives for combined hepatocellular-cholangiocarcinoma","volume":"15","author":"Auer","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00270-018-2120-z","article-title":"Percutaneous irreversible electroporation (IRE) of hepatic malignancy: a Bi-institutional analysis of safety and outcomes","volume":"42","author":"Mafeld","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"10","key":"10.1016\/j.jhep.2026.07.012_bib41","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.21873\/anticanres.12926","article-title":"Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (<4 cm) and large (>4 cm) tumors","volume":"38","author":"Jonczyk","year":"2018","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00270-011-0249-0","article-title":"Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma","volume":"35","author":"Schnapauff","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"16_suppl","key":"10.1016\/j.jhep.2026.07.012_bib43","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC)(ABC-07): results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jhep.2026.07.012_bib44","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2016.07.020","article-title":"Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I\/II institutional study","volume":"121","author":"Weiner","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jhep.2026.07.012_bib48","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/cncr.34223","article-title":"Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care and survival in the United States","volume":"128","author":"De","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib49","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis","volume":"44","author":"Mosconi","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.jhep.2026.07.012_bib50","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00270-007-9032-7","article-title":"Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma","volume":"30","author":"Herber","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.jhep.2026.07.012_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejso.2013.03.010","article-title":"Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience","volume":"39","author":"Scheuermann","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2026.07.012_bib52","first-page":"6584","article-title":"Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma","volume":"12","author":"Hu","year":"2020","journal-title":"Am J Transl Res"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10637-022-01257-z","article-title":"Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma","volume":"40","author":"Yuan","year":"2022","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12957-025-03679-4","volume":"23","author":"Song","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","article-title":"Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials","volume":"79","author":"Edeline","year":"2024","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhep.2026.07.012_bib56","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","article-title":"Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-A prospective feasibility study","volume":"34","author":"Kis","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000525489","article-title":"Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial","volume":"11","author":"Chan","year":"2022","journal-title":"Liver Cancer"},{"issue":"10","key":"10.1016\/j.jhep.2026.07.012_bib58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00270-024-03825-7","article-title":"Survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: an updated meta-analysis and meta-regression","volume":"47","author":"Cocozza","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2026.07.012_bib59","series-title":"SIRT followed by CIS-gem chemotherapy versus CIS-gem chemotherapy alone as 1st line treatment of patients with unresectable intrahepatic cholangiocarcinoma (SIRCCA)","year":"2017"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00270-025-04175-8","article-title":"Tumor absorbed dose predicts survival and local tumor control in colorectal liver metastases treated with 90Y radioembolization","volume":"49","author":"Dimopoulos","year":"2026","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.jhep.2026.07.012_bib62","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jhep.2021.07.037","article-title":"Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma","volume":"75","author":"Ricke","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib63","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.07.012_bib64","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jvir.2024.12.016","article-title":"Radiation segmentectomy and modified radiation lobectomy for unresectable early-stage intrahepatic cholangiocarcinoma","volume":"36","author":"Gupta","year":"2025","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3348\/kjr.2025.1558","article-title":"Feasibility of radioembolization with yttrium-90 resin microspheres without lung shunt fraction measurement for intrahepatic cholangiocarcinoma","volume":"27","author":"Lee","year":"2026","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jhep.2026.07.012_bib66","doi-asserted-by":"crossref","unstructured":"Chen Q.F., Hu Y., Chen S., et al. Hepatic artery infusion chemotherapy for cholangiocarcinoma in 2025. Liver Cancer 2026. [Epub ahead of print]. Available from: https:\/\/doi.org\/10.1159\/000551430","DOI":"10.1159\/000551430"},{"key":"10.1016\/j.jhep.2026.07.012_bib67","series-title":"Gemcitabine and oxaliplatin chemotherapy with or without a floxuridine and dexamethasone pump in people with cholangiocarcinoma that cannot Be removed with surgery","author":"Cercek","year":"2021"},{"key":"10.1016\/j.jhep.2026.07.012_bib68","series-title":"Additional chemotherapy administered directly into the liver using a chemo pump in patients with bile duct cancer inside the liver treatable by surgery (PUMP IV)","author":"Groot Koerkamp","year":"2024"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000362223","article-title":"Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience","volume":"59","author":"Ghiringhelli","year":"2013","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib70","article-title":"Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2026.07.012_bib71","doi-asserted-by":"crossref","first-page":"112872","DOI":"10.1016\/j.intimp.2024.112872","article-title":"Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma","volume":"140","author":"Ni","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib72","doi-asserted-by":"crossref","first-page":"19726","DOI":"10.1038\/s41598-023-47108-6","article-title":"A comparative study of clinicopathological and imaging features of HBV-negative and HBV-positive intrahepatic cholangiocarcinoma patients with different pathologic differentiation degrees","volume":"13","author":"Huang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2026.07.012_bib73","doi-asserted-by":"crossref","unstructured":"Rousian M., Alessandris R., Schleimer L., et al. Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: pooled individual patient-level analysis of four clinical trials. J Hepatol 2026. [Online ahead of print] Available from: https:\/\/doi.org\/10.1016\/j.jhep.2026.06.022","DOI":"10.1016\/j.jhep.2026.06.022"},{"issue":"7","key":"10.1016\/j.jhep.2026.07.012_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097545","article-title":"STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study","volume":"15","author":"van Loosbroek","year":"2025","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jhep.2026.07.012_bib75","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaoncol.2025.1926","article-title":"Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: a randomized clinical trial","volume":"11","author":"Xiao","year":"2025","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.jhep.2026.07.012_bib76","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"Swog S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.012_bib77","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","article-title":"Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study","volume":"276","author":"Breuer","year":"2022","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.jhep.2026.07.012_bib78","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1034\/j.1600-6143.2002.20812.x","article-title":"Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma","volume":"2","author":"Sudan","year":"2002","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib79","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/lv.2000.6143","article-title":"Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma","volume":"6","author":"De Vreede","year":"2000","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.jhep.2026.07.012_bib80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/13651820801992542","article-title":"Surgery for cholangiocarcinoma: the role of liver transplantation","volume":"10","author":"Rosen","year":"2008","journal-title":"HPB (Oxford)"},{"issue":"7","key":"10.1016\/j.jhep.2026.07.012_bib81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl Int"},{"issue":"11","key":"10.1016\/j.jhep.2026.07.012_bib82","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2026.07.012_bib84","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jvir.2022.03.024","article-title":"Outcomes of irreversible electroporation for perihilar cholangiocarcinoma: a prospective pilot study","volume":"33","author":"Franken","year":"2022","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.jhep.2026.07.012_bib85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2025.03.007","article-title":"EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma","volume":"83","author":"Marzioni","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2026.07.012_bib86","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/liv.14856","article-title":"Nationwide treatment and outcomes of perihilar cholangiocarcinoma","volume":"41","author":"van Keulen","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.07.012_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18203\/2349-3259.ijct20170303","article-title":"Protocol for a phase iii randomized trial of chemoradiation and systemic chemotherapy vs. systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma","volume":"4","author":"Chopra","year":"2017","journal-title":"Int J Clin Trials"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602739X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602739X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:55:16Z","timestamp":1789491316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782602739X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S016882782602739X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of locoregional therapies in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}